Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Prednisone in Hemophilia A: NCT03598725 Clinical Landscape Report 2026
16 October 2026
NCT03598725 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Etranacogene dezaparvovec in Hemophilia B: NCT03569891 Clinical Landscape Report 2026
16 October 2026
NCT03569891 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Turoctocog alfa in Hemophilia A: NCT03588741 Clinical Landscape Report 2026
16 October 2026
NCT03588741 clinical landscape for Hemophilia A: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BAY-1093884 in Hemophilia B: NCT03597022 Clinical Landscape Report 2026
16 October 2026
NCT03597022 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MesoPher (Amphera) in Mesothelioma: NCT03610360 Clinical Landscape Report 2026
16 October 2026
NCT03610360 clinical landscape for Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MCY-M11 in Malignant Mesothelioma of Peritoneum: NCT03608618 Clinical Landscape Report 2026
16 October 2026
NCT03608618 clinical landscape for Malignant Mesothelioma of Peritoneum: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Multi-target Gene-modified CAR-T/TCR-T Cell (Shenzhen Binde Biotechnology ) in CD19-positive B-cell acute lymphoblastic leukemia: NCT03638206 Clinical Landscape Report 2026
16 October 2026
NCT03638206 clinical landscape for CD19-positive B-cell acute lymphoblastic leukemia: endpoints, sponsor, phase, geography, readouts, asset context and devel…
9 min read
Verbrinacogene Setparvovec in Hemophilia B: NCT03641703 Clinical Landscape Report 2026
16 October 2026
NCT03641703 clinical landscape for Hemophilia B: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pemetrexed Dipotassium in Mesothelioma: NCT03655834 Clinical Landscape Report 2026
16 October 2026
NCT03655834 clinical landscape for Mesothelioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Deflazacort in Muscular Dystrophy, Duchenne: NCT03642145 Clinical Landscape Report 2026
16 October 2026
NCT03642145 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
LMB-100 in Mesothelioma, Malignant: NCT03644550 Clinical Landscape Report 2026
16 October 2026
NCT03644550 clinical landscape for Mesothelioma, Malignant: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ataluren in Muscular Dystrophy, Duchenne: NCT03648827 Clinical Landscape Report 2026
16 October 2026
NCT03648827 clinical landscape for Muscular Dystrophy, Duchenne: endpoints, sponsor, phase, geography, readouts, asset context and development white space.